Who are DA-5212's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Viagra, Tadalafil versus tamsulosin as MET, Revatio, iv sildenafil, PDE5 inhibitor (tadalafil), placebo (tadalafil).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/da-5212.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DA-5212 — Competitive Intelligence Brief

DA-5212 (DA-5212) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE5 inhibitor. Area: Cardiovascular / Regenerative Medicine.

phase 3 PDE5 inhibitor PDE5 (phosphodiesterase 5) Cardiovascular / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

DA-5212 (DA-5212) — Dong-A ST Co., Ltd.. DA-5212 is a selective inhibitor of phosphodiesterase 5 (PDE5) that enhances nitric oxide signaling to improve blood flow and tissue perfusion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DA-5212 TARGET	DA-5212	Dong-A ST Co., Ltd.	phase 3	PDE5 inhibitor	PDE5 (phosphodiesterase 5)
Viagra	sildenafil	Pfizer Inc.	marketed	PDE5 inhibitor	Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5	1998-03-27
Tadalafil versus tamsulosin as MET	Tadalafil versus tamsulosin as MET	Beni-Suef University	marketed	PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin)	PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin)
Revatio	Sildenafil Citrate	Pfizer Inc.	marketed	PDE5 inhibitor	Phosphodiesterase type 5 (PDE5)
iv sildenafil	iv sildenafil	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	PDE5 inhibitor	PDE5
PDE5 inhibitor (tadalafil)	PDE5 inhibitor (tadalafil)	Regina Elena Cancer Institute	phase 3	PDE5 inhibitor	PDE5 (phosphodiesterase type 5)
placebo (tadalafil)	placebo (tadalafil)	Eli Lilly and Company	phase 3	PDE5 inhibitor	PDE5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE5 inhibitor class)

Pfizer Inc. · 2 drugs in this class
Dong-A Pharmaceutical Co., Ltd. · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Regina Elena Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-5212 — Competitive Intelligence Brief. https://druglandscape.com/ci/da-5212. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab